Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 111, Issue 3, Pages 430-436
Publisher
Springer Nature
Online
2014-06-25
DOI
10.1038/bjc.2014.343
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
- (2013) D. P. S. Sohal et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study
- (2013) G. Rubovszky et al. EUROPEAN JOURNAL OF CANCER
- Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions
- (2013) Jesse S. Voss et al. HUMAN PATHOLOGY
- Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
- (2012) L. H. Jensen et al. ANNALS OF ONCOLOGY
- Chemotherapy for Inoperable Advanced or Metastatic Cholangiocarcinoma: Retrospective Analysis of 78 Cases in a Single Center over Four Years
- (2012) Marc Pracht et al. CHEMOTHERAPY
- Exome sequencing of liver fluke–associated cholangiocarcinoma
- (2012) Choon Kiat Ong et al. NATURE GENETICS
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
- (2011) Jeeyun Lee et al. LANCET ONCOLOGY
- Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines
- (2010) Ling Xu et al. BMC CANCER
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
- (2010) Dora Dias-Santagata et al. EMBO Molecular Medicine
- Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
- (2010) Aram F. Hezel et al. JOURNAL OF CLINICAL ONCOLOGY
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
- (2010) Sam J. Lubner et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
- (2010) Birgit Gruenberger et al. LANCET ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
- (2009) D Yoshikawa et al. BRITISH JOURNAL OF CANCER
- EGFR and HER2 expression in advanced biliary tract cancer
- (2009) Jan Harder et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
- (2008) T André et al. BRITISH JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now